Louvain-la-Neuve, Belgium, 16 September 2020 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, is pleased to announce that the Particle Therapy Interuniversity Centre Leuven (ParTICLe) in Belgium has started treating patients with proton therapy using IBA's Proteus®ONE technology. These are the first patients to receive proton beam therapy in Belgium.
The IBA compact proton therapy system installed in Leuven uses the latest generation Pencil Beam Scanning (PBS), isocenter volumetric imaging (Cone Beam CT) capabilities as well as the Philips Ambient Experience. In addition, this is the first Proteus®ONE center in the world to use the RayCare® as its oncology information system (OIS) and the first to combine Proteus®ONE technology with computed tomography (CT) on-rails imagery in the treatment room. A second cyclotron has also been installed for research purposes.
ParTICLe is an inter-university collaboration between UZ Leuven, KU Leuven, Cliniques universitaires Saint-Luc and UCLouvain, supported by UZ Gent, CHU UCL Namur, UZ Brussel and UZA. The center is focused on clinical care alongside education, training, and research & development. The installation of IBA's technology at the center means that Belgian patients will no longer need to travel abroad to access proton therapy treatment.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
IBA has been leading the proton therapy market for the last 30 years and has built the largest user community of proton therapy centers. With this additional center, 86 IBA-equipped proton therapy rooms are now in operation globally. In addition, IBA is leading innovation in proton therapy, with continued progress being made on future technologies such as ARC therapy and FLASH irradiation on its Proteus platform.
Proton therapy is the optimal choice for cancer patients where treatment options are limited or conventional radiotherapy presents an unacceptable risk to the patient. It is ideal for tumors close to vital organs and is particularly appropriate for children, whose tissue is vulnerable to damage from traditional radiation therapy. To date, around 200,000 patients(1) worldwide have already benefited from proton therapy – a figure which is expected to double in the next five years.
Olivier Legrain, Chief Executive Officer at IBA, commented: "We are delighted that patients in Belgium can now benefit from this advanced cancer treatment technology and we would like to congratulate the team at ParTICLe for this milestone. We are looking forward to continuing to expand our collaboration with the leading universities involved in this project. The close proximity of the ParTICLe Proton Therapy Center to our Headquarters should serve to further strengthen the collaboration and help advance the use of proton therapy for cancer patients in Belgium."